Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Best Noninvasive Predictor of Renal Function in Assessing Adult Sickle Nephropathy

NCT03958643 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT03958643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03958643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Best Noninvasive Predictor of Renal Function in Assessing Adult Sickle Nephropathy
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Observational
Overall status
Completed
Start date
May 24, 2019
Completion date
February 8, 2022
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease